Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 25 of 130 for:    Pancreatic Cancer | ( Map: South Korea )

The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03401827
Recruitment Status : Recruiting
First Posted : January 17, 2018
Last Update Posted : February 12, 2018
Sponsor:
Information provided by (Responsible Party):
Sang Hyub Lee, Seoul National University Hospital

Brief Summary:
Pancreatic cancer is a very poor prognosis and has a high mortality rate. The clinical results have improved somewhat with the combination therapy of chemotherapy as the first-line treatment. However, effective secondary chemotherapy after these first-line treatment failures is limited. Recently, FOLFIRINOX has been used in patients with locally advanced or metastatic pancreatic cancer who have good performance in Korea. Gemcitabine + nab-paclitaxel (GnP) as a second-line treatment after FOLFIRINOX may be expected to be considerable. The aim of this study was to evaluate the efficacy of GnP as a second-line treatment after failed FOLFIRINOX treatment for locally advanced or metastatic pancreatic ductal adenocarcinoma.

Condition or disease Intervention/treatment Phase
Pancreatic Adenocarcinoma Chemotherapy Effect Drug: Chemotherapy (Gemcitabine + nab-paclitaxel) Phase 4

Detailed Description:
Pancreatic cancer is a very poor prognosis and has a high mortality rate. It is not clear that the improvement of clinical outcome due to anticancer drugs is not clear compared to other carcinomas. In particular, the 5-year survival rate of metastatic pancreatic cancer is still only about 2%, and the clinical results have improved somewhat with the combination therapy of chemotherapy as the first-line treatment. However, effective secondary chemotherapy after these first-line treatment failures is limited. Meta-analysis has reported that life expectancy is significantly increased in patients receiving second-line chemotherapy after failure of primary chemotherapy. However, it is not yet clear which cancer treatment is most effective. In the NCCN guideline (ver. 2017.2), the second trial of chemotherapy for locally advanced or metastatic pancreatic cancer is the most recommended clinical trial.Recently, FOLFIRINOX has been used in patients with locally advanced or metastatic pancreatic cancer who have good performance in Korea. The response rate of the treatment is 30%, and many patients require secondary chemotherapy. In a practice guideline published by the American Society of Clinical Oncology, Gemcitabine + nab-paclitaxel(GnP) is the only recommended combination for patients failing primary treatment with FOLFIRINOX. In light of the results of previous reports, the efficacy of GnP as a second-line treatment after FOLFIRINOX may be expected to be considerable, but there is a lack of studies reporting GnP therapy on the second line after FOLFIRINOX failure as a first-line treatment. The aim of this study was to evaluate the efficacy of GnP as a second-line treatment after failed FOLFIRINOX treatment for locally advanced or metastatic pancreatic ductal adenocarcinoma.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer
Estimated Study Start Date : March 1, 2018
Estimated Primary Completion Date : January 1, 2019
Estimated Study Completion Date : January 1, 2019


Arm Intervention/treatment
Experimental: Gemcitabine + nab-paclitaxel
Case with chemotherapy (Gemcitabine + nab-paclitaxel)
Drug: Chemotherapy (Gemcitabine + nab-paclitaxel)

Nanoparticle albumin-bound paclitaxel (125 mg/m2) miv over 30 min, Day 1,8,15

Gemcitabine (1,000mg/m2) and N/S 150mL miv over 30 min, Day 1,8,15

Other Name: GnP




Primary Outcome Measures :
  1. survival rate [ Time Frame: 6 months ]
    survival rate at 6 months after 2nd line chemotherapy


Secondary Outcome Measures :
  1. overall survival [ Time Frame: till death or follow-up loss or end of study up to 2 years ]
    overall survival after 2nd line chemotherapy

  2. Progression free survival [ Time Frame: till death or follow-up loss or end of study up to 2 years ]
    duration till progression after 2nd line chemotherapy

  3. Disease control rate [ Time Frame: 6 months ]
    SD (stable disease) + PR (partial response) + CR (complete response) after 2nd line chemotherapy

  4. adverse event [ Time Frame: till death or follow-up loss or end of study up to 2 years ]
    all reported adverse events after 2nd line chemotherapy



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
  1. Inclusion criteria

    1. Patient whose age is 20 years or older
    2. ECOG Performance Status 0-2
    3. Pathologically confirmed pancreatic adenocarcinoma
    4. Patients with locally advanced or distant metastasis status
    5. Patients who had undergone primary chemotherapy with previous FOLFIRINOX and whose disease progress was confirmed
    6. Patients whose consent was obtained (non-insurance agreement)
  2. Exclusion Criteria

    1. Those who can not obtain consent
    2. Those who refuse chemotherapy
    3. ECOG Performance Status 3 or higher
    4. Multiple organ failure is accompanied
    5. Severe comorbidities other than cancer that do not expect a sufficient survival period over 1 month
    6. Allergy to the test drug

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03401827


Contacts
Layout table for location contacts
Contact: Jin Ho Choi, MD 82-2-2072-2228 pseudo.jh@gmail.com
Contact: Sang Hyub Lee, MD, Ph.D 82-2-2072-2228 gidoctor@korea.com

Locations
Layout table for location information
Korea, Republic of
Seoul National University Hospital Recruiting
Seoul, Korea, Republic of, 110-744
Contact: Sang Hyub Lee, MD. PhD.    +82-2-2072-4892    gidoctor@snuh.org   
Sponsors and Collaborators
Seoul National University Hospital
Investigators
Layout table for investigator information
Study Director: Sang Hyub Lee, MD, Ph.D Seoul National University Hospital

Layout table for additonal information
Responsible Party: Sang Hyub Lee, Professor, Seoul National University Hospital
ClinicalTrials.gov Identifier: NCT03401827     History of Changes
Other Study ID Numbers: H-1710-067-894
First Posted: January 17, 2018    Key Record Dates
Last Update Posted: February 12, 2018
Last Verified: January 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Sang Hyub Lee, Seoul National University Hospital:
pancreatic cancer
second line chemotherapy
nab-paclitaxel
Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatic Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Pancreatic Diseases
Adenocarcinoma
Carcinoma
Digestive System Diseases
Endocrine System Diseases
Gemcitabine
Paclitaxel
Albumin-Bound Paclitaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Antimetabolites
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs